Abstract 44: Hispanic Liver Cancer Patients are Underrepresented in Phase III Clinical Trials Conducted in the Last 10 Years

Abstract

Abstract Purpose: Hispanics bear the largest burden of liver cancer and are currently the largest subpopulation after non-Hispanic Whites in the United States (US). We aim to further characterize this burden and the inclusion of Hispanics in multinational phase III advanced liver cancer clinical trials. Methods and Results: Amongst the ten most common types of cancer in the US; we analyzed which cancer had the highest relative frequency in Hispanics compared to non-Hispanic Whites (NHW). We obtained the percentages of Hispanic individuals affected by liver cancer through the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results Program and used the Center for Disease Control and Prevention (CDC), United States Cancer Statistics (USCS) as a second database for comparison. We performed a database search using PubMed, Embase, and Web of Science: Core Collection to identify phase III clinical trials studying advanced liver cancer in the last 10 years and collected information about enrollment of Hispanic patients. A total of 13113 patients were included in phase III multinational clinical trials studying liver cancer in the last ten years. The percentage of Hispanic patients was 1.63%, 1.34% of the trial participants were NHB, 31.06 % were NHW and 46.89 % were Asian; while 32.1% had unknown racial/ethnic characteristics. However, from 2012 to 2019 the proportion HCC and BTC occurring in Hispanics was 23.2% and 22.6% respectively. Conclusions: Hispanics are disproportionately affected by liver cancer and are underrepresented in multinational phase III clinical trials in the last ten years despite having the highest relative incidence rates among the three major racial/ethnic groups in the US. Citation Format: Cecilia Monge, Tim Greten, Katherine McGlynn, Alberto Maldonado. Hispanic Liver Cancer Patients are Underrepresented in Phase III Clinical Trials Conducted in the Last 10 Years [abstract]. In: Proceedings of the 11th Annual Symposium on Global Cancer Research; Closing the Research-to-Implementation Gap; 2023 Apr 4-6. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(6_Suppl):Abstract nr 44.